Navigation Links
A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
Date:6/11/2008

Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a

New Report from Decision Resources

WALTHAM, Mass., June 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that induces closure and healing of fistulas in a greater percentage of patients than Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab) does, would earn a 30 percent patient share in the treatment of Crohn's disease, according to surveyed gastroenterologists.

The new report entitled Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab finds that surveyed gastroenterologists indicated that they would prescribe Centocor/Janssen-Cilag's ustekinumab to 30 percent of their patients with Crohn's disease. As a result, ustekinumab is forecasted to earn a 5.4 percent patient share of the U.S. Crohn's disease market in 2012.

The report also finds that UCB's Cimzia will earn Decision Resources' proprietary clinical gold standard ("clinical gold standard") status for the treatment of Crohn's disease by 2011 as interviewed gastroenterologists indicate that Cimzia's efficacy and delivery profiles are superior to those of the current clinical gold standard, Abbott/Eisai's Humira. Although surveyed gastroenterologists indicated that Cimzia has advantages in efficacy and delivery, the therapy may be associated with more minor side effects when compared to Humira.

"Interviewed gastroenterologists report that Cimzia's pegylated formulation may prolong the drug's effect, resulting in a slightly more effective maintenance therapy with a superior maintenance dosing schedule in comparison to Humira," said Kathryn Benton, analyst at Decision Resources. "As a result, we forecast Cimzia to replace Humira as the clinical gold standard because of its incremental advantage in delivery and maintenance of clinical remission."

About the Report

Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USC researchers identify genetic markers that predict efficacy of novel cancer drug
2. Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims
3. Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)
4. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
5. Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile
10. A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimers Disease Drug Market
11. What are simple ways to judge the efficacy of 5-fluorouracil in colonic neoplasm?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 19, 2017 , ... HealthSmart, the largest ... James (Jim) Vertino as Chief Information Officer (CIO). He will be joining HealthSmart ... innovation and business performance. He defines strategic roadmaps by reimagining business processes—bridging the ...
(Date:5/21/2017)... , ... May 21, 2017 , ... Florida Pain Relief ... opening of its newest location at 109 Silver Palm Ave., Melbourne, on Monday, May ... , With the opening of the Melbourne practice, PPOA operates 23 pain management clinics ...
(Date:5/19/2017)... ... 19, 2017 , ... A leader in higher education and ... recruitment efforts for the inaugural cohort of its online Master of Health ... to approach and address the unique nuances healthcare organizations face using a business-minded ...
(Date:5/19/2017)... ... May 19, 2017 , ... The ... planning assistance to families and business owners in the region, is embarking on ... MS sufferers and their families. , Multiple sclerosis (MS) is a demyelinating disease ...
(Date:5/19/2017)... Scottsdale, AZ (PRWEB) , ... May 18, 2017 , ... ... are known for being non-irritating while extremely helpful for mouth and gum health, which ... first introduced their professionals and customers learned quickly of the powerful ways in which ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... is Stroke Awareness Month and Omron Healthcare is reminding ... prevent a stroke: monitor and manage your blood pressure. ... undetected and uncontrolled hypertension is a leading risk factor ... personal heart health technology, recently evolved its mission to ... and is advancing a national public education effort to ...
(Date:5/4/2017)... , May 4, 2017 Clarius Mobile ... wireless, handheld ultrasound scanners this week at the ... Meeting (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians ... heart rate, and evaluate pregnancy-related complications like ectopic ...
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
Breaking Medicine Technology: